Synthetic hydrogel scaffold is an effective vehicle for delivery of INFUSE (rhBMP2) to critical-sized calvaria bone defects in rats

Department of Chemical and Biological Engineering, University of Colorado at Boulder, Boulder, Colorado 80309.
Journal of Orthopaedic Research (Impact Factor: 2.99). 03/2013; 31(3). DOI: 10.1002/jor.22243
Source: PubMed


Medtronic's INFUSE Bone Graft provides surgeons with a potent tool for stimulating bone formation. Current delivery vehicles that rely on Absorbable Collagen Sponges (ACS) require excessive quantities of the active ingredient in INFUSE, recombinant human Bone Morphogenic Protein-2 (rhBMP2), to achieve physiologically relevant concentrations of the growth factor, driving up the cost of the product and increasing the likelihood of undesirable side effects in neighboring tissues. We demonstrate that a simple light-mediated, thiol-ene chemistry can be used to create an effective polymer delivery vehicle for rhBMP2, eliminating the use of xenographic materials and reducing the dose of rhBMP2 required to achieve therapeutic effects. Comprised entirely of synthetic components, this system entraps rhBMP2 within a biocompatible hydrogel scaffold that is degraded by naturally occurring remodeling enzymes, clearing the way for new tissue formation. When tested side-by-side with ACS in a critical-sized bone defect model in rats, this polymeric delivery system significantly increased bone formation over ACS controls. © 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res.

6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Orthopaedics stands to benefit greatly from advances in the field of nanotechnology. By evaluating novel properties of materials, devices, and systems at the nanometer scale, investigators may be able to better mimic the extracellular milieu of the human body and use this new knowledge to further the effort of bone tissue regeneration. Nanostructured scaffolds have been designed to integrate nanotopographical features including pores, ridges, grooves, fibers, and nodes either alone or in combination to direct cellular activity. These features may prove integral in developing complex tissues that require multiple cell populations in close proximity with intricate and precise cell–cell and cell–matrix interactions. To achieve the goal of bone regeneration, biodegradable polymers, polymer blends, and composite materials have been implemented and designed accordingly. Investigators have used these materials in a variety of structures including fibers, gels, spheres, and particles for different applications. These nanoscale structures have also been used for the delivery of pharmaceuticals, proteins, and DNA. This review summarizes the current strategies to utilize composite materials for cell delivery, drug delivery, and tissue engineering for enhanced bone repair and regeneration.
    Journal of Biomaterials and Tissue Engineering 08/2013; 3(4):426-439. DOI:10.1166/jbt.2013.1098 · 2.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hypoxia inducible factor-1α (HIF-1α) plays an important role in angiogenesis-osteogenesis coupling during bone regeneration, which can enhance the bone healing capacity of mesenchymal stem cells (MSCs) by improving their osteogenic and angiogenic activity. Previous studies transduced the HIF-1α gene into MSCs with lentivirus vectors to improve their bone healing capacity. However, the risks due to lentivirus vectors, such as tumorigenesis, should be considered before clinical application. Dimethyloxalylglycine (DMOG) is a cell permeable prolyl-4-hydroxylase inhibitor, which can activate the expression of HIF-1α in cells at normal oxygen tension. Therefore, DMOG is expected to be an alternative strategy for enhancing HIF-1α expression in cells. In this study, we explored the osteogenic and angiogenic activity of adipose-derived stem cells (ASCs) treated with different concentrations of DMOG in vitro, and the bone healing capacity of DMOG-treated ASCs combined with hydrogels for treating critical-sized calvarial defects in rats. The results showed that DMOG had no obvious cytotoxic effects on ASCs and could inhibit the death of ASCs induced by serum deprivation. DMOG markedly increased VEGF production in ASCs in a dose-dependent manner and improved the osteogenic differentiation potential of ASCs by activating the expression of HIF-1α. Rats with critical-sized calvarial defects treated with hydrogels containing DMOG-treated ASCs had more bone regeneration and new vessel formation than the other groups. Therefore, we believe that DMOG enhanced the angiogenic and osteogenic activity of ASCs by activating the expression of HIF-1α, thereby improving the bone healing capacity of ASCs in rat critical-sized calvarial defects.
    Stem cells and development 12/2013; 23(9). DOI:10.1089/scd.2013.0486 · 3.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim: Use of transgenic fluorescent protein reporter mouse models to understand the cellular processes in rhBMP-2 mediated bone formation. Methods: Bilateral parietal calvarial bone defects in Col3.6Topaz transgenic fluorescent osteoblast reporter mouse were used to understand the bone formation in the presence and absence of rhBMP2 and/or Col3.6Cyan derived bone marrow derived stromal cells (BMSCs), using collagen-hydroxyapatite matrix (Healos) as a biomaterial. Results: The bone regeneration was not confined to the site of BMP-2 implantation and significant bone formation was observed in the neighboring defect site. Osteogenic cellular activity with overlying alizarin complexone staining was observed in both the defects indicating host cell induced mineralization. However, implantation of BMSCs along with rhBMP-2 demonstrated a donor cell derived bone formation. The presence of rhBMP-2 did not support host cell recruitment in the presence of donor cells. Conclusion: This study demonstrates the potential of multiple fluorescent reporters to understand the cellular processes involved in the bone regeneration process using biomaterials, growth factors and/or stem cells.
    Journal of Biomedical Materials Research Part A 03/2014; 102(12). DOI:10.1002/jbm.a.35122 · 3.37 Impact Factor
Show more